Ewing's Sarcoma

Sandra D’Angelo, MD, discussed a clinical trial on trabectedin in combination with low-dose irinotecan in Ewing sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

CHICAGO — In what researchers described as the first randomized controlled trial of chemotherapy in relapsed or refractory Ewing sarcoma, high-dose ifosfamide proved more effective in extending survival than topotecan and cyclophosphamide.